1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT)
| Autor: | Abdel-Aty, H., Amos, C.L., Brown, L.C., Yogeswaran, Y., Niem, P., Dutey-Magni, P., Kasivisvanathan, V., Bennett, R., Clarke, N., Sachdeva, A., Cross, W., Farrelly, L., Matheson, D., Peedell, C., DIEZ, P., Naismith, O., Parmar, M.K., Attard, G., van As, N., James, N.D. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S999-S999 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|